Efficacy and safety of growth hormone replacement therapy in Japanese adults with growth hormone deficiency: A postmarketing observational study

Endocrine Journal

Volumn 60, Issue 10, 2013, Pages 1131-1144

  Shimatsu, Akira ^a   Tai, Shigeru ^b,c   Imori, Makoto ^d   Ihara, Katsuichiro ^c   Taketsuna, Masanori ^e   Funai, Jumpei ^f   Tanaka, Toshiaki ^g   Teramoto, Akira ^h,i   Irie, Minoru ^j   Chihara, Kazuo ^k  

^a NATIONAL HOSPITAL ORGANIZATION KYOTO MEDICAL CENTER   (Japan)

^b Tai Clinic   (Japan)

^c Medical Science   (Japan)

^d Global Patient Safety Japan   (Japan)

^e Eli Lilly Japan KK   (Japan)

^f Science Communications   (Japan)

^g Tanaka Growth Clinic   (Japan)

^h NIPPON MEDICAL SCHOOL   (Japan)

ⁱ TOKYO ROSAI HOSPITAL   (Japan)

^j TOHO UNIVERSITY   (Japan)

^k Hyogo Prefectural Kakogawa Medical Center   (Japan)

more..

Author keywords

Adult; Growth hormone deficiency; Hormone replacement therapy; Quality of life; Safety

Indexed keywords

HUMAN GROWTH HORMONE; SOMATOMEDIN C;

ADULT; ARTHRALGIA; ARTICLE; BASAL CELL CARCINOMA; BENIGN TUMOR; BRAIN HEMORRHAGE; BRAIN INFARCTION; BREAST CANCER; CARDIOVASCULAR DISEASE; CEREBROVASCULAR ACCIDENT; CORONARY ARTERY DISEASE; CRANIOPHARYNGIOMA; DIABETES MELLITUS; DRUG EFFICACY; DRUG SAFETY; FEMALE; GERM CELL TUMOR; GLIOBLASTOMA; GLUCOSE BLOOD LEVEL; GROWTH HORMONE DEFICIENCY; HEART INFARCTION; HORMONE SUBSTITUTION; HUMAN; HYPERINSULINEMIA; HYPERLIPIDEMIA; HYPERTENSION; HYPOPHYSIS ADENOMA; HYPOPHYSIS TUMOR; HYPOTHALAMUS TUMOR; HYPOTHYROIDISM; INTESTINE POLYP; JAPANESE; KIDNEY CARCINOMA; LACUNAR STROKE; LARGE INTESTINE CANCER; LIVER FUNCTION; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MALIGNANT NEOPLASTIC DISEASE; OBSERVATIONAL STUDY; PANCREAS CARCINOMA; PERIPHERAL EDEMA; QUALITY OF LIFE; RATHKE CLEFT CYST; RHINOPHARYNGITIS; SHORT FORM 36; SIDE EFFECT; STOMACH CANCER; THYROID PAPILLARY CARCINOMA; TRIACYLGLYCEROL BLOOD LEVEL; UTERUS CANCER;

ADOLESCENT; ADULT; CARDIOVASCULAR DISEASES; DIABETES MELLITUS; FEMALE; HORMONE REPLACEMENT THERAPY; HUMAN GROWTH HORMONE; HUMANS; INSULIN-LIKE GROWTH FACTOR I; JAPAN; MALE; MIDDLE AGED; NEOPLASMS; QUALITY OF LIFE;

EID: 84887014628     PISSN: 09188959     EISSN: 13484540     Source Type: Journal    
DOI: 10.1507/endocrj.EJ13-0083     Document Type: Article

References (49)

1. Carroll PV, Christ ER, Bengtsson BÅ, Carlsson L, Christiansen JS, et al. (1998) Growth hormone deficiency in adulthood and the effects of growth hormone replacement: A review. Growth Hormone Research Society Scientific Committee. J Clin Endocrinol Metab 83: 382-395.
2. Doga M, Bonadonna S, Gola M, Mazziotti G, Giustina A (2006) Growth hormone deficiency in the adult. Pituitary 9: 305-311.
3. Monson JP (2003) Long-term experience with GH replacement therapy: Efficacy and safety. Eur J Endocrinol 148 Suppl 2: S9-14.
4. Attanasio AF, Lamberts SW, Matranga AM, Birkett MA, Bates PC, et al. (1997) Adult growth hormone (GH)-deficient patients demonstrate heterogeneity between childhood onset and adult onset before and during human GH treatment. Adult Growth Hormone Deficiency Study Group. J Clin Endocrinol Metab 82: 82-88.
5. Rosilio M, Blum WF, Edwards DJ, Shavrikova EP, Valle D, et al. (2004) Long-term improvement of quality of life during growth hormone (GH) replacement therapy in adults with GH deficiency, as measured by questions on life satisfaction-hypopituitarism (QLS-H). J Clin Endocrinol Metab 89: 1684-1693.
6. Björk S, Jönsson B, Westphal O, Levin JE (1989) Quality of life of adults with growth hormone deficiency: a controlled study. Acta Paediatr Scand Suppl 356: 55-59; discussion 60, 73-4.
7. Rosen T, Wiren L, Wilhelmsen L, Wiklund I, Bengtsson BÅ (1994) Decreased psychological well-being in adult patients with growth hormone deficiency. Clin Endocrinol (Oxf) 40: 111-116.
8. Wallymahmed ME, Baker GA, Humphris G, Dewey M, MacFarlane IA (1996) The development, reliability and validity of a disease specific quality of life model for adults with growth hormone deficiency. Clin Endocrinol (Oxf) 44: 403-411.
9. Shimatsu A, Tai S, Tanaka T, Fujieda K, Teramoto A, et al. (2011) Clinical characteristics of Japanese adults with growth hormone deficiency: a HypoCCS database study. Endocr J 58: 325-333.
10. Nilsson AG, Svensson J, Johannsson G (2007) Management of growth hormone deficiency in adults. Growth Horm IGF Res 17: 441-462.
11. Blum WF, Shavrikova EP, Edwards DJ, Rosilio M, Hartman ML, et al. (2003) Decreased quality of life in adult patients with growth hormone deficiency compared with general populations using the new, validated, self-weighted questionnaire, questions on life satisfaction hypopituitarism module. J Clin Endocrinol Metab 88: 4158-4167.
12. Peker Y, Svensson J, Hedner J, Grote L, Johannsson G (2006) Sleep apnoea and quality of life in growth hormone (GH)-deficient adults before and after 6 months of GH replacement therapy. Clin Endocrinol (Oxf) 65: 98-105.
13. Koltowska-Häggström M, Mattsson AF, Shalet SM (2009) Assessment of quality of life in adult patients with GH deficiency: KIMS contribution to clinical practice and pharmacoeconomic evaluations. Eur J Endocrinol 161 Suppl 1: S51-64.
14. Molitch ME, Clemmons DR, Malozowski S, Merriam GR, Vance ML, et al. (2011) Evaluation and treatment of adult growth hormone deficiency: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 96: 1587-1609.
15. Chihara K, Fujieda K, Shimatsu A, Miki T, Tachibana K (2010) Dose-dependent changes in body composition during growth hormone (GH) treatment in Japanese patients with adult GH deficiency: A randomized, placebo-controlled trial. Growth Horm IGF Res 20: 205-211.
16. Chihara K, Kato Y, Kohno H, Takano K, Tanaka T, et al. (2006) Efficacy and safety of growth hormone (GH) in the treatment of adult Japanese patients with GH deficiency: A randomised, placebo-controlled study. Growth Horm IGF Res 16: 132-142.
17. Chihara K, Kato Y, Shimatsu A, Tanaka T, Kohno H (2008) Efficacy and safety of individualized growth hormone treatment in adult Japanese patients with growth hormone deficiency. Growth Horm IGF Res 18: 394-403.
18. Chihara K, Koledova E, Shimatsu A, Kato Y, Kohno H, et al. (2004) Adult GH deficiency in Japanese patients: effects of GH treatment in a randomised, placebo-controlled trial. Eur J Endocrinol 151: 343-350.
19. Chihara K, Koledova E, Shimatsu A, Kato Y, Kohno H, et al. (2005) An individualized GH dose regimen for long-term GH treatment in Japanese patients with adult GH deficiency. Eur J Endocrinol 153: 57-65.
20. Urushihara H, Fukuhara S, Tai S, Morita S, Chihara K (2007) Heterogeneity in responsiveness of perceived quality of life to body composition changes between adult-and childhood-onset Japanese hypopituitary adults with GH deficiency during GH replacement. Eur J Endocrinol 156: 637-645.
21. Chihara K, Kato Y, Kohno H, Takano K, Tanaka T, et al. (2008) Safety and efficacy of growth hormone (GH) during extended treatment of adult Japanese patients with GH deficiency (GHD). Growth Horm IGF Res 18: 307-317.
22. Webb SM, Strasburger CJ, Mo D, Hartman ML, Melmed S, et al. (2009) Changing patterns of the adult growth hormone deficiency diagnosis documented in a decadelong global surveillance database. J Clin Endocrinol Metab 94: 392-399
23. Attanasio AF, Bates PC, Ho KK, Webb SM, Ross RJ, et al. (2002) Human growth hormone replacement in adult hypopituitary patients: long-term effects on body composition and lipid status--3-year results from the HypoCCS Database. J Clin Endocrinol Metab 87: 1600-1606.
24. Humatrope [prescribing information] (2010) Kobe, Japan: Eli Lilly Japan K.K.
25. Kashiwagi A, Kasuga M, Araki E, Oka Y, Hanafusa T, et al. (2012) International clinical harmonization of glycated hemoglobin in Japan: From Japan Diabetes Society to National Glycohemoglobin Standardization Program values. J Diabet Invest 3: 39-40.
26. Fukuhara S, Bito S, Green J, Hsiao A, Kurokawa K (1998) Translation, adaptation, and validation of the SF-36 Health Survey for use in Japan. J Clin Epidemiol 51: 1037-1044.
27. Suzukamo Y, Noguchi H, Takahashi N, Shimatsu A, Chihara K, et al. (2006) Validation of the Japanese version of the Quality of Life-Assessment of Growth Hormone Deficiency in Adults (QoL-AGHDA). Growth Horm IGF Res 16: 340-347.
28. Shimatsu A, Chihara K, Hizuka N, Teramoto A, Tanaka T, et al. (2007) Reference intervals of serum insulin-like growth factor-I in adult Japanese population: calculated with LMS methods. Horumon to Rinsho 55: 393-399 (in Japanese).
29. Fukuhara S, Suzukamo Y, Manual of SF-36v2 Japanese version. 2009, Kyoto: Institute for Health Outcomes and Process Evaluation Research.
30. Kaji H, Sakurai T, Iguchi G, Murata M, Kishimoto M, et al. (2002) Adult growth hormone deficiency in Japan: Results of investigation by questionnaire. Endocr J 49: 597-604.
31. Johannsson G, Bjarnason R, Bramnert M, Carlsson LM, Degerblad M, et al. (1996) The individual responsiveness to growth hormone (GH) treatment in GH-deficient adults is dependent on the level of GH-binding protein, body mass index, age, and gender. J Clin Endocrinol Metab 81: 1575-1581.
32. Ezzat S, Fear S, Gaillard RC, Gayle C, Marcovitz S, et al. (2003) Circulating IGF-I levels in monitoring and predicting efficacy during long-term GH treatment of GH-deficient adults. Eur J Endocrinol 149: 499-509.
33. Barbosa EJ, Koranyi J, Filipsson H, Bengtsson BÅ, Boguszewski CL, et al. (2010) Models to predict changes in serum IGF1 and body composition in response to GH replacement therapy in GH-deficient adults. Eur J Endocrinol 162: 869-878.
34. Mukherjee A, Adams JE, Smethurst L & Shalet SM. (2005) Interdependence of lean body mass and total body water, but not quality of life measures, during low dose GH replacement in GH-deficient adults. Eur J Endocrinol 153: 661-668.
35. Abs R, Bengtsson BÅ, Hernberg-Stahl E, Monson JP, Tauber JP, et al. (1999) GH replacement in 1034 growth hormone deficient hypopituitary adults: Demographic and clinical characteristics, dosing and safety. Clin Endocrinol (Oxf) 50: 703-713.
36. Hartman ML, Xu R, Crowe BJ, Robison LL, Erfurth EM, et al. (2013) Prospective safety surveillance of GH-deficient adults: comparison of GH-treated vs untreated patients. J Clin Endocrinol Metab 98: 980-988.
37. Hatrick AG, Boghalo P, Bingham JB, Ayres AB, Sonksen PH, et al. (2002) Does GH replacement therapy in adult GH-deficient patients result in recurrence or increase in size of pituitary tumours? Eur J Endocrinol 146: 807-811.
38. Buchfelder M, Kann PH, Wüster C, Tuschy U, Saller B, et al. (2007) Influence of GH substitution therapy in deficient adults on the recurrence rate of hormonally inactive pituitary adenomas: A case control study. Eur J Endocrinol 157: 149-156.
39. Bell J, Parker KL, Swinford RD, Hoffman AR, Maneatis T, et al. (2010) Long-term safety of recombinant human growth hormone in children. J Clin Endocrinol Metab 95: 167-177.
40. Brada M, Ford D, Ashley S, Bliss JM, Crowley S, et al. (1992) Risk of second brain tumour after conservative surgery and radiotherapy for pituitary adenoma. BMJ 304: 1343-1346.
41. Child CJ, Zimmermann AG, Woodmansee WW, Green DM, Li JJ, et al. (2011) Assessment of primary cancers in GH-treated adult hypopituitary patients: An analysis from the Hypopituitary Control and Complications Study. Eur J Endocrinol 165: 217-223.
42. Waki K, Noda M, Sasaki S, Matsumura Y, Takahashi Y, et al. (2005) Alcohol consumption and other risk factors for self-reported diabetes among middle-aged Japanese: A population-based prospective study in the JPHC study cohort I. Diabetic Med 22: 323-331.
43. Noda M, Kato M, Takahashi Y, Matsushita Y, Mizoue T, et al. (2010) Fasting plasma glucose and 5-year incidence of diabetes in the JPHC diabetes study-suggestion for the threshold for impaired fasting glucose among Japanese. Endocr J 57: 629-637.
44. Attanasio AF, Jung H, Mo D, Chanson P, Bouillon R, et al. (2011) Prevalence and incidence of diabetes mellitus in adult patients on growth hormone replacement for growth hormone deficiency: A surveillance database analysis. J Clin Endocrinol Metab 96: 2255-2261.
45. Luger A, Mattsson AF, Koltowska-Häggström M, Thunander M, Góth M, et al. (2012) Incidence of diabetes mellitus and evolution of glucose parameters in growth hormone-deficient subjects during growth hormone replacement therapy: A long-term observational study. Diabetes Care 35: 57-62.
46. Turin TC, Kokubo Y, Murakami Y, Higashiyama A, Rumana N, et al. (2010) Lifetime risk of stroke in Japan. Stroke 41: 1552-1554.
47. Turin TC, Kokubo Y, Murakami Y, Higashiyama A, Rumana N, et al. (2010) Lifetime risk of acute myocardial infarction in Japan. Circ Cardiovasc Qual Outcomes 3: 701-703.
48. Svensson J, Bengtsson BÅ, Rosen T, Oden A, Johannsson G (2004) Malignant disease and cardiovascular morbidity in hypopituitary adults with or without growth hormone replacement therapy. J Clin Endocrinol Metab 89: 3306-3312.
49. Erfurth EM, Hagmar L (2005) Cerebrovascular disease in patients with pituitary tumors. Trends Endocrinol Metab 16: 334-342.